Literature DB >> 23871605

Reprogramming fibroblasts into bipotential hepatic stem cells by defined factors.

Bing Yu1, Zhi-Ying He, Pu You, Qing-Wang Han, Dao Xiang, Fei Chen, Min-Jun Wang, Chang-Cheng Liu, Xi-Wen Lin, Uyunbilig Borjigin, Xiao-Yuan Zi, Jian-Xiu Li, Hai-Ying Zhu, Wen-Lin Li, Chun-Sheng Han, Kirk J Wangensteen, Yufang Shi, Li-Jian Hui, Xin Wang, Yi-Ping Hu.   

Abstract

Recent studies have demonstrated direct reprogramming of fibroblasts into a range of somatic cell types, but to date stem or progenitor cells have only been reprogrammed for the blood and neuronal lineages. We previously reported generation of induced hepatocyte-like (iHep) cells by transduction of Gata4, Hnf1α, and Foxa3 in p19 Arf null mouse embryonic fibroblasts (MEFs). Here, we show that Hnf1β and Foxa3, liver organogenesis transcription factors, are sufficient to reprogram MEFs into induced hepatic stem cells (iHepSCs). iHepSCs can be stably expanded in vitro and possess the potential of bidirectional differentiation into both hepatocytic and cholangiocytic lineages. In the injured liver of fumarylacetoacetate hydrolase (Fah)-deficient mice, repopulating iHepSCs become hepatocyte-like cells. They also engraft as cholangiocytes into bile ducts of mice with DDC-induced bile ductular injury. Lineage conversion into bipotential expandable iHepSCs provides a strategy to enable efficient derivation of both hepatocytes and cholangiocytes for use in disease modeling and tissue engineering.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23871605     DOI: 10.1016/j.stem.2013.06.017

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  68 in total

Review 1.  Expression kinetics of hepatic progenitor markers in cellular models of human liver development recapitulating hepatocyte and biliary cell fate commitment.

Authors:  Pooja Chaudhari; Lipeng Tian; Abhijeet Deshmukh; Yoon-Young Jang
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-06

2.  A small molecule Hedgehog agonist HhAg1.5 mediated reprogramming breaks the quiescence of noninjured liver stem cells for rescuing liver failure.

Authors:  Abhisek Mitra; Jun Yan; Liangfang Zhang; Shulin Li
Journal:  Transl Res       Date:  2018-10-19       Impact factor: 7.012

3.  New Tools in Experimental Cellular Therapy for the Treatment of Liver Diseases.

Authors:  Jennifer R Ferrer; Attasit Chokechanachaisakul; Jason A Wertheim
Journal:  Curr Transplant Rep       Date:  2015-06-01

4.  Shortcut route for generation of functional hepatocyte cells from human skin allogenically for autologous treatment of chronic liver diseases.

Authors:  Shibashish Giri; Augustinus Bader
Journal:  J Clin Exp Hepatol       Date:  2014-04-18

5.  Novel direct reprogramming technique for the generation of culture-expandable cardiac progenitor cells from fibroblasts.

Authors:  Masaaki Ii
Journal:  Stem Cell Investig       Date:  2017-02-16

6.  Reversible transition between hepatocytes and liver progenitors for in vitro hepatocyte expansion.

Authors:  Han Wu; Xu Zhou; Gong-Bo Fu; Zhi-Ying He; Hong-Ping Wu; Pu You; Charles Ashton; Xin Wang; Hong-Yang Wang; He-Xin Yan
Journal:  Cell Res       Date:  2017-04-04       Impact factor: 25.617

7.  Generation of multipotent induced cardiac progenitor cells from mouse fibroblasts and potency testing in ex vivo mouse embryos.

Authors:  Pratik A Lalit; Adriana M Rodriguez; Karen M Downs; Timothy J Kamp
Journal:  Nat Protoc       Date:  2017-04-20       Impact factor: 13.491

8.  Direct Conversion of Cord Blood CD34+ Cells Into Neural Stem Cells by OCT4.

Authors:  Wenbin Liao; Nick Huang; Jingxia Yu; Alexander Jares; Jianchang Yang; Gary Zieve; Cecilia Avila; Xun Jiang; Xiao-Bing Zhang; Yupo Ma
Journal:  Stem Cells Transl Med       Date:  2015-05-13       Impact factor: 6.940

Review 9.  Direct lineage reprogramming via pioneer factors; a detour through developmental gene regulatory networks.

Authors:  Samantha A Morris
Journal:  Development       Date:  2016-08-01       Impact factor: 6.868

Review 10.  Cellular therapy for liver disease.

Authors:  Robert C Huebert; Jorge Rakela
Journal:  Mayo Clin Proc       Date:  2014-03       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.